Analysts view Legend Biotech's current valuations as a buying opportunity.
1 report, 0 independent
Updated Jun 26
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Analysts view Legend Biotech's current valuations as a buying opportunity.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.- Royal Bank of Canada cut its price target on Legend Biotech in a research report.Sub-event
- Analysts view Legend Biotech's valuation as a buying opportunity.
Keep exploring
The entities involved
-
Legend Biotech
Biotech company
Nothing else this week.
-
Royal Bank of Canada
financial institution in Canada
Related events
- Legend Biotech and BioTech, both healthcare companies, are currently competing for investment.
- Royal Bank of Canada has provided buy ratings and price targets for AeroVironment.
- Financial institutions are currently analyzing both Royal Bank of Canada and Truist Financial.
- Benchmark reduced its price target and set a buy rating for Abbott Laboratories, while Royal Bank of Canada issued an outperform rating on July 29, 2026.
- Royal Bank of Canada reiterated an outperform rating, and TD Securities restated a buy rating for ATS Corporation.
Coverage
Newest first; wire copies grouped- Unknown outlet